Last reviewed · How we verify
NCT05428215
Comparison of PKs of 17-Beta-Estradiol Via Sublingual Placement Versus Swallowing in Male-to-Female Transgender Patients
Phase 4 trial testing 17beta Estradiol in Gender Dysphoria in 2 participants. Terminated before completion.
20 July 2023
Quick facts
| Lead sponsor | MaineHealth |
|---|---|
| Phase | Phase 4 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 2 |
| Start date | 29 December 2022 |
| Primary completion | 20 July 2023 |
| Estimated completion | 20 July 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- 17beta Estradiol — full drug profile →
Conditions studied
- Gender Dysphoria — all drugs for Gender Dysphoria →
Sponsor
MaineHealth — full company profile →
Who can join
18 and older, male only, with Gender Dysphoria. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This crossover study will investigate the pharmacokinetics of oral versus sublingual administration of 17-beta-estradiol in the trans-female population.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05428215
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of 17beta Estradiol
Trials testing the same drug.
- NCT03018366 — Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women · Phase 2 · completed
- NCT00059228 — Clinical Trial of Estrogen for Postpartum Depression · Phase 2 · terminated
Other recruiting trials for Gender Dysphoria
Currently open trials in the same condition.
- NCT06969326 — Topical Estrogen: Brief Intervention to Improve Postoperative Experience for Transgender Men Undergoing Hysterectomy · Phase 3 · recruiting
- NCT07147166 — Evaluating the Efficacy of Force Modulating Tissue Bridge Device in Preventing Hypertrophic Scars Following Gender-Affir · NA · recruiting
- NCT06639776 — Sexual Functioning After Erection Prosthesis Placement in Post Phalloplasty Transgender Persons · recruiting
- NCT06639763 — Erectile Aid Use in Post-phalloplasty and Post-metoidioplasty Transgender Patients · recruiting
- NCT06351501 — Evaluation of the Effectiveness of Hormonal Treatment in Adolescents Suffering from Gender Dysphoria · Phase 3 · recruiting
Other MaineHealth trials
Trials by the same sponsor.
- NCT07228494 — Comparative Study of Simulation Technologies for Use in Neonatal Resuscitation Training for Rural Hospitals · NA · not yet recruiting
- NCT06869993 — Giving Healthy Meal Kits and Cooking Lessons to Rural Families With Food Insecurity. · NA · completed
- NCT06169501 — Mindfulness Intervention for Caregivers of Autism in Rural Environments · NA · suspended
- NCT06266793 — Comparison of Holmium Laser and Thulium Laser for Mini PCNL · NA · enrolling by invitation
- NCT05377970 — Implementation of a Prehabilitation Program for Surgical Patients · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05428215 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by MaineHealth
- Last refreshed: 27 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05428215.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing